KING OF PRUSSIA, Pa., Jan 26, 2021
If you or a family member have sought care from a mental health professional, or are considering seeking help for depression, anxiety, ADHD or other conditions, you want the best treatment available. Multiple treatment options now exist for many of these conditions, ranging from medications and psychotherapy to alternative treatments. It can be confusing to sort through your choices and determine what approach will give you or your loved one the ideal outcome.
Since the pandemic began, many have felt the effects on their mental health. The CDC reported in June that over 40% of Americans suffered an adverse mental or behavioral health condition, with anxiety and depressive disorders topping the list. By mid-July, 53% of U.S. adults said their mental health was negatively impacted by stress and worry due to the pandemic, according to a Kaiser Family Foundation poll. As the pandemic continues, these stressors are likely to impact more people every day.
New patent-pending, real-time polymerase chain reaction (PCR) technique can accurately detect the human leukocyte antigen HLA-A*31:01 genetic variant, reducing the 40% false positive rate associated with the industry testing approach. Genomind’s® Professional PGx Express™ is now the only mental health pharmacogenetics (PGx) test using this capability in the market. Given the recent positive coverage decisions by major health insurers, Genomind will be leading national education efforts to make this innovation widely available to clinicians and patients